- Work +44 20 7269 8550
Patents - biotechnology, chemistry and pharmaceuticals group.
Catherine has represented clients before the EPO since 1991. She has an enviable direct client list and substantial experience in successfully defending and opposing patents at the EPO in the petrochemical, agrochemical and therapeutic arenas. In addition to multi-party oppositions, Catherine has taken a coordinating role in pan-European litigation. As well as large organisations, Catherine enjoys working directly with emerging companies, in areas such as gene therapy, natural products, pharmaceuticals, diagnostics, catalysis, to build value through their IP portfolio. This has often involved IP due diligence for mergers, project acquisitions and flotations. Particularly, through her work on bioinformatics-based and vaccine cases, Catherine has gained experience at all levels before the EPO concerning the amount of data needed to file a patent application. Along with Charles Harding, Catherine has been involved in a number of strategic oppositions for Oxford Biomedica. Catherine continues to successfully represent Martek Biosciences Corporation in Europe and has recently successfully maintained a patent before the EPO Board of Appeal (T-0261/08) against an opposition by a commercial competitor. This was a seminal case on commercial production of micro-organisms for obtaining beneficial omega-3 fatty acids. The case also decided that the status of an opposition can be passed to a universal successor. She is also involved, with Charles Harding and Zije Clyde-Watson in advising Merial on a pan European litigation relating to Frontline TM and Frontline Plus TM (veterinary products containing fipronil for treating fleas in cats and dogs). The FR limb of the litigation was successful - at both the Court of First Instance and on appeal. The DE limb of this litigation will go to trial in July 2012 and the UK limb of this litigation is expected to continue into 2012. Catherine has acquired the following new clients this year: Vitaflo International and Great Ormond Street Hospital. In 2010, Catherine and Simon O'Brien were involved in the due diligence associated with the completion of a share capital increase, with acquisition of new financial resources of €57.8m, for Molmed SPA. Catherine heads a team serving clients which include Oxford Biomedica, Martek Biosciences Corporation, MolMed SPA, Lubrizol and Fondazione Centro San Raffaele Del Monte Tabor. Catherine is regularly recommended in independent legal publications. Legal 500 2011 stated: "On the life sciences side, Catherine Mallalieu is 'very reliable' and has an 'excellent legal and scientific background'". In 2010 Catherine was referred to by Legal 500 as "'excellent' on pharmaceutical and biotech matters" (Legal 500 2010). Catherine has also been "singled out for praise" by Chambers in 2010 and is "clearly in the premier league of patent attorneys covering biotech in the UK" according to the Managing Intellectual Property (MIP) IP Handbook 2010.
European patent attorney 1991; chartered patent attorney 1991; European design attorney. D Young & Co, partner 1997; Catherine had in-house patent experience with Zeneca Agrochemicals with particular responsibility for their bioscience division and in their insecticide division.
Chartered Institute of Patent Attorneys (CIPA) and the CIPA patents committee; European Patent Institute (epi); American Intellectual Property Law Association (AIPLA).
University of Birmingham (BSc in Chemistry).